Signaling Pathway
Burosumab is a human monoclonal antibody that selectively neutralizes fibroblast growth factor 23 (FGF23). This antibody is employed in the study of disorders such as X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia, offering significant insights into the pathophysiological mechanisms and potential therapeutic targets for these conditions.
重要通知：仅供研究使用。我们不向患者销售。
| Discription | Burosumab is a human monoclonal antibody that selectively neutralizes fibroblast growth factor 23 (FGF23). This antibody is employed in the study of disorders such as X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia, offering significant insights into the pathophysiological mechanisms and potential therapeutic targets for these conditions. |
||
|---|---|---|---|
| Targets |
|
Calculate the dilution required to prepare a stock solution. This equation is commonly abbreviated as: C1V1 = C2V2
